Skip to search formSkip to main contentSkip to account menu

vorapaxar

Known as: [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-Fluorophényl)-2-pyridinyl]vinyl}-1-méthyl-3-oxododécahydronaphto[2,3-c]furan-6-yl]carbamate d'éthyle, Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester, Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamate 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (3)

LactonesPlatelet Aggregation InhibitorsPyridines

Narrower (2)

SCH-530348vorapaxar sulfate
vorapaxar 2.08 MG Oral Tablet [Zontivity]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function
Patients with renal disease are often undertreated with antiplatelet therapy due to concerns about bleeding. Vorapaxar blocks… 
Review
2018
Review
2018
The PAR 1 antagonist , SCH 79797 , alters platelet morphology and function indepen-dently of PARs
doi:10.1160/TH12-06-0389 Thromb Haemost 2013; 109: 164–167 Dear Sirs, Protease-activated receptors (PARs) are a family of four G… 
2017
2017
Abstract 15480: The Efficacy and Safety of More Potent Antiplatelet Therapy With Vorapaxar in Patients With Impaired Renal Function: Insights From the TRA 2P-TIMI 50 Trial
Introduction: Patients with renal disease are often undertreated with antiplatelet therapy due to concerns about bleeding… 
2017
2017
Ischaemic disorders: Safe path to thrombosis prevention
effectively reduce atherothrombotic events in patients at high risk, but the use of such agents has been associated with a risk… 
Review
2015
Review
2015
PAR 1 Receptor / Protein Interactions 1 From Multiple PAR 1 Receptor / Protein Interactions to their Multiple Therapeutic Implications
PAR1, member of the family of protease-activated receptors, is a GPCR whose activation requires a proteolytic cleavage at its… 
2015
2015
Vorapaxar, a novel oral antiplatelet drug
Vorapaxor is first in the class of protease activated receptor 1 (PAR 1) antagonists. It acts by inhibiting the binding of… 
2015
2015
Vorapaxar Has Greater Net Benefit in Patients with Diabetes
Vorapaxar is a new type of antiplatelet agent that blocks thrombin-induced activation at the protease activated receptor 1. In… 
Review
2013
Review
2013
High on-treatment platelet reactivity - why should we be concerned?
Antiplatelet drugs are the cornerstone in prevention and treatment of atherothrombotic vessel occlusions, i.e. myocardial… 
2012
2012
Vorapaxar expands antiplatelet options.
Vorapaxar is the first substance of a new class of antiplatelet drugs that has been tested in large clinical trials. The protease… 
2010
2010
Identification of Human Liver Cytochrome P450 Enzymes Involved in the Metabolism of SCH 530348 (Vorapaxar), a Potent Oral Thrombin (PAR1) Receptor Antagonist
Vorapaxar (SCH 530348), a potent oral thrombin receptor (PAR-1) antagonist, is being developed as an antiplatelet agent for…